Demographic and clinical characteristics of patients with both psoriasis and vitiligo in a cohort of vitiligo patients: a cross‐sectional study

Canu, D.; Shourick, Jason; Andreu, Nicolas; Gey, A.; Ballanger-Désolneux, F.; Barailler, H.; Boniface, Katia; Ezzedine, Khaled; Sénéschal, Julien

doi:10.1111/jdv.17383

Cited by 10 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Canu et al described demographic and clinical characteristics of patients with both psoriasis and vitiligo in a cohort of patients: particularly, of the 436 vitiligo patients included in this study, 74 vitiligo patients (45 women) had a past and/or current personal history of psoriasis. The authors suggested that patients with vitiligo and psoriasis are more prone to a combination of a Th17‐ and Th1‐skewed immune response, referring to the presence in psoriatic skin of memory CD8 + T cells directed against the melanocyte‐derived protein ADAMTSL5 that may favor the development of vitiligo in a predisposed patient 5 …”

Section: Discussionmentioning

confidence: 99%

“…TNF‐α is supposed to be as potential cytokine involved in the vitiligo pathogenesis. In fact, anti‐TNF‐α agents have been used in treatment of vitiligo with uncertain results, even if in vivo studies demonstrated that TNF‐α inhibits differentiation of melanocytes from stem cells 5 . The relationship between psoriasis and melanogenesis, as well as the connection between biologics and vitiligo, has yet to be confirmed.…”

Section: Discussionmentioning

confidence: 99%

“…The authors suggested that patients with vitiligo and psoriasis are more prone to a combination of a Th17-and Th1-skewed immune response, referring to the presence in psoriatic skin of memory CD8 + T cells directed against the melanocyte-derived protein ADAMTSL5 that may favor the development of vitiligo in a predisposed patient. 5 Vitiligo has been reported an idiosyncratic adverse effect of anti-TNFα agents including adalimumab. TNF-α is supposed to be as potential cytokine involved in the vitiligo pathogenesis.…”

Section: Discussionmentioning

confidence: 99%

“…In fact, anti-TNF-α agents have been used in treatment of vitiligo with uncertain results, even if in vivo studies demonstrated that TNF-α inhibits differentiation of melanocytes from stem cells. 5 The relationship between psoriasis and melanogenesis, as well as the connection between biologics and vitiligo, has yet to be confirmed. One case of TNFα induced vitiligo, resolved after ixekizumab therapy, has recently been described.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Onset of vitiligo in a psoriasis patient on ixekizumab

Marasca

Fornaro

Fabbrocini

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Introduction Vitiligo is an acquired skin disorder clinically characterized by hypopigmentated macules and patches. Psoriasis is a chronic‐inflammatory‐skin‐condition characterized by erythematous‐plaques covered with scales particularly over the extensor‐surfaces, scalp, and lumbosacral region. Recent major‐researches‐advancements have significantly expanded our understanding of psoriasis‐pathophysiology, resulting in the development of highly effective targeted‐therapies, such as anti TNFα, IL‐12/23‐inhibitors, IL‐17‐inhibitors, or IL‐23‐inhibitors. Particularly, ixekizumab, a humanized‐monoclonal immunoglobulin‐G 4 antibody, specifically binding IL‐17A, demonstrated strong efficacy in threating recalcitrant psoriasis. Nevertheless, paradoxical reactions due to IL‐17 inhibitors have been described. Case report Herein, we report the case of a 53‐year‐old Caucasian man who obtained complete skin clearance of psoriasis plaques after 16 weeks of ixekizumab treatment together with the appearance of vitiligo patches localized on the facial area. He had never suffered of vitiligo and his family history excluded vitiligo diagnosis. We also could exclude post inflammatory psoriasis hypopigmentation because of absence of facial involvement at baseline. Our experience suggests that vitiligo might be considered a rare adverse effects of anti‐IL‐17 therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Onset of vitiligo in a psoriasis patient on ixekizumab

Marasca

Fornaro

Fabbrocini

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…However, 11 months into treatment he developed extensive new-onset vitiligo affecting his trunk, limbs, and face (Figure 1 ixekizumab induces a skewed Th17/Th1 response whereby Th1-secreted cytokines activate natural killer cells and cytotoxic CD8+ T cells that target melanocytes. 2,3 Furthermore, autoantigens that have been amplified by biologic therapy produce autoantibodies that may result in melanocyte destruction, a theory that was proposed in anti-TNF alpha-induced vitiligo. 4 Other biologics commonly used in the treatment of psoriasis that have been reported to induce vitiligo include secukinumab (IL-17 inhibitor) and ustekinumab (IL-12/23 inhibitor).…”

mentioning

confidence: 99%